GLP-1 Drugs Explained: Classes, Mechanism & Selection Guide

GLP-1 drugs are a class of medications that activate the glucagon-like peptide-1 receptor, a protein that regulates blood glucose levels, appetite signaling, and gastric emptying. This drug class includes over 10 FDA-approved medications and dozens of compounded formulations, each with distinct mechanisms, onset times, and clinical profiles.

Understanding which GLP-1 drugs exist, how they differ, and which may align with your metabolic health goals requires both clinical evidence and personalized assessment. PlexusDx emphasizes precision wellness: knowing your genetic predispositions in peptide metabolism can support a more informed conversation with your provider about formulation choice, dosing strategy, and expected outcomes.

The GLP-1 Receptor Agonist Drug Class: Mechanism and Historical Context

GLP-1 receptor agonists were first developed in the early 2000s for type 2 diabetes management. Exenatide (Byetta), a synthetic version of a protein found in Gila monster venom, was the first-in-class agent. Since then, the drug class has expanded significantly, with both short-acting and long-acting formulations now available across injectable, oral, and dual-compound platforms.

The mechanism centers on GLP-1 receptor activation in the pancreas, brain, and gastrointestinal tract. This binding stimulates insulin secretion in response to glucose, slows gastric emptying, increases satiety signaling in the hypothalamus, and may promote beta-cell preservation. Different drugs in this class have varying receptor affinity, half-life, and tissue selectivity, influencing their clinical profile and tolerability.

FDA-Approved GLP-1 Drugs: Classification by Formulation and Duration

The GLP-1 drug landscape includes injectable and oral formulations, each with distinct pharmacokinetic profiles. Injectable agents dominate prescribing due to higher receptor occupancy and more rapid glycemic response. Oral options have emerged more recently, offering convenience but requiring careful dosing strategies to maintain bioavailability. Understanding these differences supports informed provider dialogue about which formulation may fit your lifestyle and clinical goals.

Beyond FDA-Approved Agents: Compounded GLP-1 and Tirzepatide Options

Licensed 503A compounding pharmacies now prepare semaglutide and tirzepatide formulations that mirror FDA-approved active ingredients but allow for flexible dosing, concentrated delivery, and personalized peptide protocols. These compounded versions are not FDA-approved drugs but are lawfully prepared under pharmacy regulations when prescribed by a licensed provider for individual patient use.

PlexusDx partners exclusively with licensed 503A compounders to offer compounded semaglutide injections (starting at $179/month), oral semaglutide ($249/mo), compounded tirzepatide injections ($249/mo), and oral tirzepatide ($279/mo). Microdose GLP-1 protocols ($129/month) and dual-compound formulations like GLP-Squared ($249/mo) provide additional precision options. These are distinct from branded medications and require provider oversight.

Genetic Predispositions and Biomarker Context in GLP-1 Selection

Individual variation in GLP-1 receptor expression, insulin secretion capacity, and appetite-signaling pathways influences how each person responds to GLP-1 agonists. Genetic variants in GLP1R, GIPR, FTO, and MC4R genes may provide context about your baseline metabolic phenotype and predisposition toward appetite sensitivity, glucose handling, and weight regulation—though genetics alone do not predict exact medication response.

PlexusDx's Precision Peptide Genetic Test ($99 add-on or $298 standalone) analyzes key variants: GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313. This test reveals predispositions in peptide genetic pathways, allowing your provider to contextualize whether a pure GLP-1 agonist, a dual GLP-1/GIP agent, or a specific dosing strategy may align better with your metabolic profile. Results should be interpreted with a qualified healthcare provider to inform personalized formulation and dosing decisions.

Safety, Eligibility, and Provider Oversight in GLP-1 Selection

GLP-1 agonists carry well-characterized risks: gastrointestinal side effects (nausea, vomiting, diarrhea), potential pancreatitis (rare), and thyroid C-cell concerns in animal studies. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and certain diabetic retinopathy phenotypes. Pregnancy, active malignancy, and severe renal or hepatic disease warrant careful provider evaluation.

Determining which GLP-1 drug class and formulation is appropriate requires comprehensive medical assessment by a licensed healthcare provider. Your provider will evaluate fasting glucose, A1c, kidney function, cardiovascular history, prior medication tolerability, and lifestyle factors. Genetic predisposition data from the Precision Peptide Test may support that conversation, but genetic information should never replace clinical judgment. PlexusDx providers use a structured assessment process to match patients with appropriate formulations and dosing protocols.

How PlexusDx Supports a More Personalized Approach

The Precision Peptide Genetic Test may help provide context about your individual predispositions in GLP-1 receptor pathway function, appetite regulation genes (FTO, MC4R), and GIP co-receptor sensitivity. Understanding whether your genetic profile suggests stronger appetite-signaling responsiveness or differential glucose-handling capacity can support a more informed conversation with your provider about whether a pure GLP-1 agonist, a dual GLP-1/GIP agent like tirzepatide, or a specific dosing strategy may be more appropriate for your metabolic phenotype.

PlexusDx's genetic test reveals predispositions but does not predict exact medication response or guarantee outcomes. Genetic variants in GLP1R, GIPR, FTO, and MC4R represent risk factors and tendencies, not deterministic markers. Your provider must interpret these results alongside clinical labs, medical history, and real-world response to any medication. The test is designed to contextualize your baseline metabolic health and support shared decision-making—not to replace medical evaluation or clinical oversight.

If you are considering GLP-1 therapy—whether compounded semaglutide, tirzepatide, or a dual-compound formulation—PlexusDx recommends discussing genetic predisposition data and biomarker context with your healthcare provider to ensure the selected drug class, formulation, and dosing protocol align with your health goals and metabolic profile. This precision-wellness approach can help optimize both efficacy and tolerability.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

• History Of Glp 1 Drugs Plexusdx
• Glp 1 Agonist Drugs
• Glp 1 Drugs List
• Drugs Glp 1